Interleukin-33 Promotes Disease Progression in Patients with Primary Biliary Cirrhosis

• Published in: The Tohoku Journal of Experimental Medicine Vol. 234; no. 4; pp. 255 - 261
• Main Authors: Sun, Yongqiang, Zhang, Ji-Yuan, Lv, Sa, Wang, Huan, Gong, Man, Du, Ning, Liu, Honghong, Zhang, Ning, Jing, Jing, Zhou, Chao, Zhang, Fan, Wang, Zongren
• Format: Journal Article
• Language: English
• Published: Japan Tohoku University Medical Press 01-12-2014
• Subjects: Chemotaxis; Disease Progression; Humans; immune pathogenesis; Interleukin-33; Interleukins - blood; Interleukins - metabolism; Liver - metabolism; Liver - pathology; Liver Cirrhosis, Biliary - blood; Liver Cirrhosis, Biliary - metabolism; Liver Cirrhosis, Biliary - pathology; liver lesion; Middle Aged; Neutrophils - metabolism; primary biliary cirrhosis
• ISSN: 0040-8727; 1349-3329
• DOI: 10.1620/tjem.234.255

Primary biliary cirrhosis (PBC) is a progressive autoimmune liver disease that can cause a series of complications, including cirrhosis, liver failure and hepatocellular carcinoma. Interleukin-33 (IL-33) is expressed in various non-hematopoietic cells and a certain population of immune cells, and exerts its biological effects by binding to the specific receptor, suppression of tumorigenicity 2 (ST2). A soluble form of ST2 (sST2) has been postulated to act as a decoy receptor for IL-33. In this study, we aimed to investigate the role of IL-33 in the pathogenesis of PBC. The study included 20 healthy controls and 68 patients with PBC. We thus found the increased serum IL-33 levels in PBC patients. Its elevated levels were positively correlated with serum alkaline phosphatase levels (a key parameter for the definition of PBC) and with Child-Pugh scores, which were used to determine the prognosis of liver cirrhosis. Moreover, the serum concentrations of sST2 were significantly higher in PBC patients compared with healthy subjects, irrespective of the disease severity. Importantly, the cells that express IL-33 and/or myeloperoxidase (a marker for neutrophils) were accumulated in the livers of PBC patients, and their number increased with the severity of liver lesions. Lastly, in vitro chemotaxis assays revealed that IL-33 enhanced the migration of neutrophils. These data suggest that IL-33 may affect the progress of PBC by recruiting neutrophils to the liver. This expanded knowledge of IL-33 in PBC patients is important for developing therapeutic strategies (e.g., neutralization of IL-33), selecting optimal clinical management, and predicting prognosis.